Table 3.
Summary of results for reporting and analysing for follow-up information and handling of attrition
| Main analysis | DS1 | DS2 | |
| N | 211 | 131 | 115 |
| Reporting of patients lost to follow-up | 69 (33%) | 47 (36%) | 44 (38%) |
| Reporting of patients lost to follow-up by treatment | 30 (14%) | 26 (20%) | 24 (21%) |
| Reporting of patients changing/stopping treatment | 101 (48%) | 75 (57%) | 64 (56%) |
| Reporting of reasons for treatment discontinuation | 62 (29%) | 47 (36%) | 41 (36%) |
| Handling of attrition in the analysis (in studies with outcome other than retention) | 44/177 (25%) | 31/106 (29%) | 28/95 (29%) |
| Method to handle attrition (when acknowledged)* | |||
| Non-responder imputation | 27/44 (62%) | 22/31 (71%) | 20/28 (72%) |
| Complete case | 8/44 (18%) | 5/31 (16%) | 5/28 (18%) |
| Last observation carried forward | 8/44 (18%) | 4/31 (12%) | 2/28 (7%) |
| Other | 8/44 (18%) | 7/31 (23%) | 6/28 (21%) |
DS1: Dataset 1 includes only studies where the comparison of at least two treatments was the main exposure of interest (head to head studies).
DS2: Dataset 2 includes only studies from DS1, which had no other outcome than effectiveness.
*Sum of the methods may be greater than the numbers of studies as some studies used several methods.